An oral, rising single-dose tolerance, pharmacokinetic, and pharmacodynamic study of Pf-00184562 capsules in healthy volunteers

Trial Profile

An oral, rising single-dose tolerance, pharmacokinetic, and pharmacodynamic study of Pf-00184562 capsules in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Olanzapine; PF 184562
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top